Australia · Delayed Price · Currency is AUD Pharmx Technologies Earnings Call Transcripts
Fiscal Year 2026
-
FY 2026 saw strong revenue and recurring growth, led by Marketplace and analytics, with positive EBITDA despite increased investment. Strategic alliances, platform modernization, and AI initiatives set the stage for margin expansion and accelerated growth in FY 2027.
-
Revenue grew 3% to AUD 3.9 million with strong Marketplace and New Zealand performance, positive EBITDA, and a major strategic partnership with Sigma Chemist Warehouse. Marketplace adoption and supplier integration surged, supporting future growth.
Fiscal Year 2025
-
FY 2025 saw 13% revenue growth to AUD 7.5M, strong platform metrics, and improved gross margin, despite higher investment in people and technology. Marketplace revenues tripled, and the cash position remains robust. FY 2026 will focus on platform integration and marketplace expansion.
-
Revenue grew 17% year-over-year, driven by strong performance in core and marketplace platforms, expansion into New Zealand, and new analytics offerings. Despite higher investment and a major legal settlement, profitability improved and the cash position remains strong.